The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

被引:178
|
作者
Kempf, DJ
Rode, RA
Xu, Y
Sun, E
Heath-Chiozzi, ME
Valdes, J
Japour, AJ
Danner, S
Boucher, C
Molla, A
Leonard, JM
机构
[1] Abbott Labs, Antiviral Venture, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Dept Biostat, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Dept Infect Dis Res, Abbott Pk, IL 60064 USA
[4] Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Utrecht, Univ Hosp, Eijkman Winkler Inst Med & Clin MIcrobiol, Utrecht, Netherlands
关键词
viral load; durability of response; protease inhibitor; resistance;
D O I
10.1097/00002030-199805000-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine markers that are associated with the durability of virologic response to therapy with HIV protease inhibitors in HIV-infected individuals. Design: This study encompassed two retrospective analyses of the duration of virologic response to protease inhibitor therapy. The first analysis included 29 patients receiving either monotherapy or combination therapy with the protease inhibitor ritonavir whose plasma HIV RNA levels rebounded from the point of greatest decline with mutations associated with resistance to ritonavir. The second analysis included a cohort of 102 patients who initially responded to randomized treatment with either monotherapy with ritonavir or combination therapy with ritonavir and zidovudine. Methods: Durability of response was defined as the time from the initiation of therapy to the point at which plasma HIV RNA displayed a sustained increase of at least 0.6 log(10) copies/ml from the nadir value. In the first analysis, durability of response was analyzed with respect to baseline HIV RNA, HIV RNA at the nadir, and the drop in HIV RNA from baseline to the nadir. In the second analysis, time to rebound was examined using Kaplan-Meier analysis, stratifying by either baseline HIV RNA or HIV RNA at the nadir. Results: In both analyses, the durability of response was not highly associated with either baseline RNA or the magnitude of RNA decline from baseline. Instead, a strong relationship was observed between the durability of response and the nadir plasma HIV-1 RNA value (P < 0.01). The nadir in viral load was generally reached after 12 weeks of randomized therapy. Conclusions: Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy. Therapeutic strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response before the emergence of high level resistance should be investigated. (C) 1998 Rapid Science Ltd.
引用
收藏
页码:F9 / F14
页数:6
相关论文
共 50 条
  • [41] Optimal timing and duration of induction therapy for HIV-1 infection
    Curlin, Marcel E.
    Iyer, Shyamala
    Mittler, John E.
    PLOS COMPUTATIONAL BIOLOGY, 2007, 3 (07) : 1239 - 1256
  • [42] Plasma RNA viral load is not associated with intrapatient quasispecies heterogeneity in HIV-1 infection
    Bello, G
    Casado, C
    García, S
    Rodríguez, C
    del Romero, J
    Borderia, AV
    López-Galíndez, C
    ARCHIVES OF VIROLOGY, 2004, 149 (09) : 1761 - 1771
  • [43] Efficient Suppression of Minority Drug-Resistant HIV Type 1 (HIV-1) Variants Present at Primary HIV-1 Infection by Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Therapy
    Metzner, Karin J.
    Rauch, Pia
    von Wyl, Viktor
    Leemann, Christine
    Grube, Christina
    Kuster, Herbert
    Boeni, Juerg
    Weber, Rainer
    Guenthard, Huldrych F.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (07): : 1063 - 1071
  • [44] Plasma RNA viral load is not associated with intrapatient quasispecies heterogeneity in HIV-1 infection
    G. Bello
    C. Casado
    S. García
    C. Rodríguez
    J. del Romero
    A. V. Borderia
    C. López-Galíndez
    Archives of Virology, 2004, 149 : 1761 - 1771
  • [45] HIV-1 RNA in blood and pathogenesis of HIV infection
    Saksela, K
    ANNALS OF MEDICINE, 1995, 27 (06) : 625 - 628
  • [46] Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence
    Pomerantz, RJ
    AIDS, 2001, 15 (10) : 1201 - 1211
  • [47] HIV-1 Tat is present in the serum of people living with HIV-1 despite viral suppression
    Shmakova, Anna
    Tsimailo, Ivan
    Kozhevnikova, Yana
    Gerard, Laurence
    Boutboul, David
    Oksenhendler, Eric
    Tuaillon, Edouard
    Rivault, Aurelie
    Germini, Diego
    Vassetzky, Yegor
    Beaumelle, Bruno
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 142
  • [48] N6-methyladenosine of HIV-1 RNA regulates viral infection and HIV-1 Gag protein expression
    Tirumuru, Nagaraja
    Zhao, Boxuan Simen
    Lu, Wuxun
    Lu, Zhike
    He, Chuan
    Wu, Li
    ELIFE, 2016, 5
  • [49] Rapid viral suppression using integrase inhibitors during acute HIV-1 infection
    Mckellar, Mehri S.
    Keys, Jessica R.
    Filiatreau, Lindsey M.
    Mcgee, Kara S.
    Kuruc, Joann D.
    Ferrari, Guido
    Margolis, David M.
    Eron, Joseph J.
    Hicks, Charles B.
    Gay, Cynthia L.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 80 (01) : 169 - 174
  • [50] Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
    Picchio, GR
    Valdez, H
    Sabbe, R
    Landay, AL
    Kuritzkes, DR
    Lederman, MM
    Mosier, DE
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (04) : 289 - 295